Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical Development

Forward Therapeutics Completes Phase 1 Trials, Advances FT2109 to Phase 2

Forward Therapeutics, Inc. has successfully completed Phase 1 first-in-human trials for two internally-discovered oral small molecule TNF signaling inhibitors, FT2109 and FT751. Following a comprehensive assessment of the data, FT2109 has been selected as the lead candidate for advancement into Phase 2 clinical development. FT2109 is designed to selectively target soluble TNF, aiming to improve safety and therapeutic activity across various inflammation-driven diseases by preserving regulatory and host defense functions, differentiating it from broader anti-TNF biologics. Both candidates demonstrated promising safety and pharmacologic profiles in their respective Phase 1 programs.

• Successful Phase 1 Completion and Lead Candidate Selection: Forward Therapeutics announced the successful completion of Phase 1 first-in-human trials for its two internally-discovered oral TNF signaling inhibitors, FT2109 and FT751. Based on a comprehensive evaluation of the safety and pharmacologic profiles from both programs, FT2109 was selected as the lead candidate due to its overall, potentially best-in-class profile, and will now advance into Phase 2 clinical development for inflammation-driven diseases.
• Differentiated Mechanism of Action for FT2109: FT2109 is a next-generation oral small molecule designed to selectively inhibit TNFR1 signaling by binding to soluble TNF (sTNF), a primary driver of chronic inflammatory diseases. This selective approach aims to overcome limitations of existing injectable anti-TNF biologics, such as the need for injections, elevated infection risk, demyelinating events, paradoxical responses, and anti-drug antibody formation, by improving efficacy, safety, adherence, and durability.
• Proprietary Drug Discovery Engine: The company leverages its proprietary SWIFT™ data-driven drug discovery engine to build its portfolio of novel oral small molecule therapies. This engine combines curated, drug-like libraries with elaborated screening assays and deep structural insights, enabling rapid hit finding and lead optimization for high-potential, hard-to-drug targets, thereby supporting the development of candidates like FT2109.

Addressing Current Treatment Gaps in Inflammation-Driven Diseases

Current treatment approaches for inflammation-driven diseases face substantial limitations despite decades of therapeutic advancement. These challenges span from inadequate efficacy in addressing underlying pathophysiology to significant gaps in available therapeutic options across multiple disease areas.

• Cardiovascular Disease Limitations: Despite modern therapeutic approaches in primary and secondary cardiovascular prevention, cardiovascular diseases remain the leading cause of mortality worldwide, with no approved anti-inflammatory agents specifically indicated for silencing inflammation in patients with coronary artery disease until canakinumab's breakthrough in 2017

• Therapeutic Development Complexity: Development of anti-inflammatory therapy has been challenging due to the complexity of specific inflammatory processes underlying diseases like atherosclerosis and the dual nature of inflammation as both a pathological driver and protective response against microorganisms

• Disease-Specific Treatment Failures: Current treatments for pulmonary arterial hypertension in connective tissue diseases fail to be completely curative with poor patient prognosis, while therapies for rheumatoid arthritis often fail to fully address the intricate pathophysiology, particularly inflammatory proliferation and hypoxic microenvironment in synovial tissue

• Diabetic Complications Management: Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of diabetic retinopathy patients continues growing with limited therapeutic approaches and significant limitations and side effects associated with current therapies

• Interstitial Lung Disease Challenges: Management of interstitial lung disease, especially idiopathic pulmonary fibrosis, remains both difficult and unsatisfactory, with many patients only receiving supportive therapy and anti-inflammatory treatment results varying from no improvement to significant survival prolongation

• Economic and Prognostic Barriers: Anti-inflammatory therapy is costly to administer and monitor, particularly in developing countries, while despite newer treatment strategies for conditions like interstitial lung disease, overall prognosis has not substantially changed over the past 30 years

• Pediatric Treatment Gaps: Limited pediatric-specific trial data exists for conditions like myocarditis, with treatment direction continuing to rely on extrapolation from adult studies and corticosteroid investigations showing mixed results with improvements in ventricular function but unclear survival benefits

Positioning FT2109 in the Evolving Inflammation Landscape

Recent clinical evidence demonstrates a paradigm shift in inflammation treatment approaches, with investigational therapies showing significant advantages over conventional standard-of-care options. Plant-derived extracellular vesicles (PDEVs) have emerged as biocompatible, multi-target agents that effectively attenuate inflammation and promote tissue repair while overcoming the drug delivery barriers and toxicity limitations inherent to conventional NSAIDs and biologics. Traditional Chinese medicine combined with Western therapies has demonstrated superior clinical outcomes in COVID-19 patients, achieving higher cure rates, improved lung inflammation resolution, and shorter hospital stays compared to Western medicine alone, while reducing C-reactive protein levels through bidirectional regulation of inflammatory cells rather than simple inflammation suppression.

Cardiovascular inflammation management has witnessed notable therapeutic advances, with IL-1 inhibitors and colchicine demonstrating significant reductions in cardiovascular events and marking a transition toward immune-targeted therapies. Canakinumab's selective IL-1β neutralization reduces major adverse cardiovascular events independently of lipid lowering, establishing inflammation as a therapeutically actionable pathway in atherosclerotic disease. However, standard treatments including statins and anti-platelet drugs prevent only 30-40% of major cardiovascular events, highlighting the clinical need for novel anti-inflammatory approaches. Immune checkpoint inhibitors and CAR T-cell therapies, originally developed for oncology and autoimmune conditions, are under evaluation for cardiovascular applications, though the complex interplay between cytokine signaling, autoimmunity, and vascular injury determines both therapeutic benefit and toxicity profiles.

Across multiple inflammation-driven conditions, investigational approaches demonstrate superior efficacy profiles compared to standard care. In rheumatoid arthritis, biologic DMARDs targeting specific molecular pathways show advantages over traditional therapies, with tofacitinib demonstrating favorable safety and efficacy outcomes versus conventional disease-modifying antirheumatic drugs. Low-dose colchicine has emerged as an effective cardiovascular protection strategy, while dose optimization studies reveal that low-dose celecoxib may offer superior safety and efficacy compared to standard dosing in osteoarthritis by preserving physiological prostaglandin E2 levels. These findings collectively indicate that investigational therapies are addressing fundamental limitations of conventional anti-inflammatory treatments, including incomplete symptom relief, significant adverse effects, and suboptimal long-term outcomes.

FT2109: A New Oral Frontier in Selective TNF Inhibition

The pharmaceutical landscape for inflammatory diseases is poised for potential evolution with Forward Therapeutics' decision to advance FT2109, an oral small molecule TNF signaling inhibitor, into Phase 2 clinical development. This move follows encouraging Phase 1 results for both FT2109 and FT751, signaling a strategic push into a highly competitive, yet therapeutically critical, area.

What makes FT2109 particularly noteworthy is its proposed mechanism of action: a selective targeting of soluble TNF. This approach aims to differentiate it from existing broader anti-TNF biologics by preserving essential regulatory and host defense functions. If successful, this selectivity could translate into a more favorable safety profile and enhanced therapeutic activity, potentially addressing some of the limitations associated with current, less selective TNF inhibitors. The convenience of an oral small molecule formulation further amplifies its potential impact, offering a significant advantage in patient adherence and accessibility over injectable treatments.

However, the path forward is not without its challenges. Key considerations include:

• The promising Phase 1 safety and pharmacologic data for FT2109 must be rigorously validated in larger, more diverse patient cohorts during Phase 2 trials to confirm its clinical differentiation.

• The established market dominance of existing anti-TNF biologics and the emergence of other oral small molecules mean FT2109 will enter a crowded therapeutic space, necessitating clear evidence of superior benefit-risk.

• The theoretical advantage of selective soluble TNF inhibition must demonstrably translate into tangible clinical benefits, such as improved efficacy, reduced side effects, or a broader therapeutic window, to justify its adoption.

Should FT2109 successfully navigate these hurdles, it could represent a significant step forward, offering a new generation of targeted therapy for inflammation-driven diseases. Its potential to offer a safer, more convenient, and equally or more effective treatment option could redefine patient expectations and treatment paradigms in this critical therapeutic area.